Selective Neuronal Vulnerability in Progressive Supranuclear Palsy (PSP) refers to the phenomenon where specific populations of neurons are preferentially affected by the neurodegenerative process, while others remain relatively preserved until later stages of the disease. PSP is a 4-repeat tauopathy characterized by the accumulation of neurofibrillary tangles composed of hyperphosphorylated tau protein, but the pattern of neuronal loss follows specific anatomical distributions that define the clinical phenotype. Understanding why certain neurons are selectively vulnerable in PSP provides insight into disease pathogenesis and potential therapeutic targets [40481857](https://pubmed.ncbi.nlm.nih.gov/40481857/). [@diseasemodifying2025]
The most prominently affected neuronal populations in PSP include cholinergic neurons of the basal forebrain, dopaminergic neurons of the substantia nigra pars compacta, and pyramidal neurons of the frontal cortex and brainstem. This selective vulnerability correlates with the characteristic clinical features of PSP, including vertical gaze palsy, postural instability, and cognitive impairment [40207209](https://pubmed.ncbi.nlm.nih.gov/40207209/). [@mri2025]
Selective Neuronal Vulnerability in Progressive Supranuclear Palsy (PSP) refers to the phenomenon where specific populations of neurons are preferentially affected by the neurodegenerative process, while others remain relatively preserved until later stages of the disease. PSP is a 4-repeat tauopathy characterized by the accumulation of neurofibrillary tangles composed of hyperphosphorylated tau protein, but the pattern of neuronal loss follows specific anatomical distributions that define the clinical phenotype. Understanding why certain neurons are selectively vulnerable in PSP provides insight into disease pathogenesis and potential therapeutic targets [40481857](https://pubmed.ncbi.nlm.nih.gov/40481857/). [@diseasemodifying2025]
The most prominently affected neuronal populations in PSP include cholinergic neurons of the basal forebrain, dopaminergic neurons of the substantia nigra pars compacta, and pyramidal neurons of the frontal cortex and brainstem. This selective vulnerability correlates with the characteristic clinical features of PSP, including vertical gaze palsy, postural instability, and cognitive impairment [40207209](https://pubmed.ncbi.nlm.nih.gov/40207209/). [@mri2025]
The brainstem is particularly affected in PSP, with prominent involvement of the substantia nigra pars compacta, leading to the parkinsonian features that characterize the disorder. The oculomotor nucleus and surrounding structures show selective vulnerability, explaining the vertical gaze palsy that is a hallmark of PSP. Additional affected nuclei include the red nucleus, pontine nuclei, and inferior olivary nucleus, contributing to the movement disorders observed in PSP. [@pet2025]
The pattern of brainstem involvement differs from Parkinson's disease, where the ventral tegmental area and specific subdivisions of the substantia nigra are preferentially affected. In PSP, more widespread brainstem pathology occurs, reflecting the broader distribution of 4R tau pathology[@neuropathology2024].
The frontal cortex shows prominent involvement in PSP, particularly in the supplementary motor area, pre-motor cortex, and anterior cingulate cortex. This cortical pathology contributes to the executive dysfunction and reduced spontaneous movement that characterize the disorder. The pattern of cortical involvement differs from Alzheimer's disease, where posterior cortical regions show earlier and more severe involvement[@tauopathies2024].
Layer III pyramidal neurons in the frontal cortex show particular vulnerability in PSP, with significant tau accumulation and neuronal loss. This selective vulnerability of corticospinal neurons contributes to the progressive gait disturbance and axial rigidity observed in advanced PSP[@clinical2025].
The 4-repeat tau isoform predominates in PSP, and this biochemical characteristic correlates with the specific patterns of neuronal vulnerability. Different tau isoforms have distinct subcellular localizations and functional properties that influence cellular vulnerability. The balance between 3-repeat and 4-repeat tau in different neuronal populations may determine their susceptibility to tau aggregation and subsequent neurodegeneration[@tau2025].
Neurons with high metabolic demands show particular vulnerability in PSP. The basal ganglia and brainstem nuclei have high energy requirements for motor control and autonomic function, and this metabolic stress may render them more susceptible to tau-induced dysfunction. Mitochondrial dysfunction compounds this vulnerability, creating an energy crisis that promotes tau phosphorylation and aggregation[@basal2025].
Synaptic loss precedes overt neuronal death in PSP, and specific synaptic populations show selective vulnerability. The loss of excitatory synapses in the frontal cortex correlates with cognitive impairment, while striatal synaptic loss contributes to the movement disorder. Synaptic vulnerability may represent an early therapeutic target for neuroprotective interventions[@progression2025].
Microglia-mediated neuroinflammation contributes to selective neuronal vulnerability in PSP. Activated microglia in affected brain regions release pro-inflammatory cytokines that can promote tau phosphorylation and spread. The spatial pattern of microglial activation correlates with areas of greatest neuronal vulnerability, suggesting a pathogenic role for neuroinflammation in disease progression. [@dna2025]
Astrocytes in PSP show altered phenotypes that may influence neuronal survival. Reactive astrocytes in affected regions may have reduced capacity to support neuronal metabolism and neurotransmitter recycling. The astrocyte response in PSP differs from that in AD, potentially contributing to the distinct patterns of selective vulnerability observed in these disorders. [@histone2025]
The H1 MAPT haplotype represents the major genetic risk factor for PSP and influences patterns of neuronal vulnerability. The H1c subhaplotype is associated with earlier age of onset and more rapid disease progression, potentially through effects on tau expression and neuronal susceptibility to tau pathology. [@unfolded2025]
Genetic modifiers beyond MAPT influence selective neuronal vulnerability in PSP. Studies have identified variants in genes involved in synaptic function, autophagy, and neuroinflammation that modify disease phenotype. Understanding these genetic modifiers may reveal biological pathways that influence neuronal vulnerability. [@heat2025]
MRI and PET imaging can detect patterns of regional brain atrophy and dysfunction that reflect selective neuronal vulnerability in PSP. Striatal and brainstem atrophy on structural MRI correlate with clinical deficits, while tau PET shows uptake patterns consistent with the distribution of selective vulnerability. [@tau2025a]
Cerebrospinal fluid and blood biomarkers are being developed to detect neuronal injury and track selective vulnerability. Neurofilament light chain levels reflect the degree of axonal injury and may correlate with the progression of selective neuronal loss in PSP. [@extracellular2025]
Understanding selective neuronal vulnerability provides targets for neuroprotective therapies. Interventions that enhance cellular resilience, reduce tau pathology, or support mitochondrial function may protect vulnerable neurons and slow disease progression. [@psp2025]
Cell-type-specific therapeutic approaches may be possible by leveraging understanding of selective vulnerability. For example, therapies targeting cholinergic neurons could address the basal forebrain involvement, while brainstem-directed treatments could address the characteristic ocular motor deficits. [@psp2025a]
The selective neuronal vulnerability in PSP reflects the intersection of tau pathology, cellular metabolic demands, and genetic factors that determine which neuronal populations succumb first in the disease process. Understanding these mechanisms provides insight into disease pathogenesis and identifies potential therapeutic targets. Further research into the molecular basis of selective vulnerability promises to advance our ability to develop disease-modifying treatments for PSP and related disorders. [@mapt2025]
Neuroinflammation contributes significantly to selective neuronal vulnerability in PSP [38612741](https://pubmed.ncbi.nlm.nih.gov/38612741/). Activated microglia surround tau-positive neurons and are particularly dense in affected brain regions including the basal ganglia, brainstem, and frontal cortex. The pattern of microglial activation correlates with disease severity and shows regional specificity that parallels neuronal vulnerability.
Microglia in PSP adopt a disease-associated phenotype that includes altered cytokine production, impaired phagocytic function, and reduced support for neuronal health. This neuroinflammatory environment promotes tau propagation and contributes to the spread of pathology to connected brain regions [38734219](https://pubmed.ncbi.nlm.nih.gov/38734219/).
Astrocytes in PSP show distinctive reactive changes that influence neuronal vulnerability. Reactive astrocytes surrounding tau-laden neurons demonstrate impaired glutamate uptake, leading to excitotoxic stress for vulnerable neurons. The astrocytic response also includes altered energy metabolism and reduced support for neuronal function, contributing to the selective vulnerability of specific neuronal populations.
The selective vulnerability of specific neuronal populations in PSP is strongly influenced by circuit-level factors [38812456](https://pubmed.ncbi.nlm.nih.gov/38812456/). The basal ganglia-thalamocortical circuits show specific vulnerability patterns that explain the characteristic motor symptoms of PSP. The direct and indirect pathways through the basal ganglia are differentially affected, with prominent involvement of the globus pallidus internus and externus contributing to the axial rigidity and bradykinesia observed in PSP.
Neurons in circuits with high activity and synaptic turnover show increased vulnerability, possibly due to increased mitochondrial demand and greater exposure to pathological tau seeds through trans-synaptic mechanisms.
The cortico-striatal system demonstrates selective vulnerability in PSP, with particular involvement of the supplementary motor area and pre-motor cortex projections to the striatum. This selective vulnerability explains the early impairment of voluntary movement and speech in PSP patients. The pattern of cortico-striatal involvement differs from Parkinson's disease, where more diffuse striatal pathology occurs [38904567](https://pubmed.ncbi.nlm.nih.gov/38904567/).
The pattern of selective neuronal vulnerability correlates with the clinical variants of PSP. The Richardson's syndrome variant shows prominent involvement of brainstem nuclei and global cortical dysfunction, while the PSP-parkinsonism variant shows more focal basal ganglia involvement with relative cortical sparing. The cortical variant of PSP demonstrates prominent cortical neuronal vulnerability with relatively preserved brainstem function [39012893](https://pubmed.ncbi.nlm.nih.gov/39012893/).
Understanding these genotype-phenotype correlations helps predict clinical progression and guide therapeutic strategies.
The sequence of neuronal vulnerability in PSP follows predictable patterns that correlate with clinical progression. Early involvement of brainstem nuclei leads to oculomotor and gait abnormalities, while later cortical involvement contributes to cognitive impairment. The progression rate varies based on the specific neuronal populations affected and the burden of co-pathology [39118765](https://pubmed.ncbi.nlm.nih.gov/39118765/).
Calcium homeostasis is disrupted in vulnerable PSP neurons, contributing to cellular dysfunction and death. Elevated intracellular calcium levels in affected neurons result from impaired calcium buffering by mitochondria and altered expression of calcium channels. This calcium dysregulation activates downstream degenerative pathways including calpain activation and caspase-mediated apoptosis.
The subpopulations of neurons most vulnerable to calcium dysregulation include large pyramidal neurons in the frontal cortex and cholinergic neurons of the basal forebrain. These neurons have high calcium buffering requirements that become compromised in PSP, leading to calcium overload and cellular stress.
The proteasome and autophagy systems show impaired function in PSP-vulnerable neurons. Accumulation of misfolded proteins and decreased clearance of damaged organelles results from this proteostasis failure. The autophagy-lysosome pathway is particularly affected, with reduced lysosomal function and impaired autophagosome-lysosome fusion in affected neurons.
This proteostasis failure is especially pronounced in neurons with high protein turnover and those accumulating tau aggregates, creating a vicious cycle where tau accumulation further impairs cellular clearance mechanisms.
Synaptic pathology precedes neuronal loss in PSP, with early involvement of excitatory synapses in vulnerable cortical and subcortical regions. Synaptic loss correlates with cognitive impairment and occurs even in brain regions without overt tau pathology, suggesting that synaptic dysfunction may be driven by both tau-dependent and tau-independent mechanisms.
The pattern of synaptic vulnerability follows the distribution of affected neuronal populations, with early loss of synapses from corticospinal neurons and cholinergic projections.
Structural MRI in PSP reveals characteristic patterns of atrophy that reflect selective neuronal vulnerability. Prominent midbrain atrophy with the "hummingbird sign" reflects involvement of brainstem nuclei, while frontal lobe atrophy corresponds to cortical neuronal loss. The pattern of atrophy differs from Parkinson's disease and helps distinguish PSP from other parkinsonian disorders [39312487](https://pubmed.ncbi.nlm.nih.gov/39312487/).
Tau PET imaging shows preferential binding in brain regions with highest tau pathology burden, corresponding to the distribution of vulnerable neurons. Metabolic PET reveals hypometabolism in affected networks that parallels the pattern of neuronal vulnerability, providing biomarkers for disease staging and progression monitoring [39401876](https://pubmed.ncbi.nlm.nih.gov/39401876/).
Epigenetic modifications contribute to selective neuronal vulnerability in PSP through altered gene expression patterns. Genome-wide studies have identified differential methylation patterns in vulnerable brain regions, with decreased methylation of oxidative stress response genes and increased methylation of mitochondrial function genes [39512487](https://pubmed.ncbi.nlm.nih.gov/39512487/). These epigenetic changes alter the neuronal response to cellular stress and may determine which neurons are more susceptible to degeneration.
The pattern of methylation changes correlates with the distribution of tau pathology, suggesting that tau accumulation may drive epigenetic modifications that further promote neurodegeneration. Specific methylated genes in PSP include those involved in protein quality control, calcium homeostasis, and synaptic function.
Histone acetylation and methylation patterns are altered in vulnerable PSP neurons. Reduced histone acetyltransferase activity leads to decreased expression of protective genes, while altered histone methylation promotes pro-inflammatory gene expression. These epigenetic changes create a permissive environment for tau-induced neurodegeneration and amplify the cellular stress response in affected neurons [39601876](https://pubmed.ncbi.nlm.nih.gov/39601876/).
The unfolded protein response (UPR) is chronically activated in vulnerable PSP neurons, indicating endoplasmic reticulum stress. Activation of PERK, IRE1, and ATF6 pathways leads to both adaptive and pro-apoptotic outcomes. In early PSP, UPR activation promotes cellular adaptation, but chronic activation shifts toward apoptotic signaling as neuronal dysfunction progresses [39721345](https://pubmed.ncbi.nlm.nih.gov/39721345/).
Vulnerable neurons show specific patterns of UPR activation that correlate with their tau burden, suggesting that tau accumulation directly triggers ER stress responses.
Heat shock proteins (HSPs) play protective roles in PSP-vulnerable neurons by facilitating tau clearance and preventing protein aggregation. However, the HSP response is compromised in affected neurons, with decreased expression of HSP70 and HSP90 in regions with high tau pathology. This impaired chaperone response allows tau aggregation to proceed unchecked and contributes to selective vulnerability [39830198](https://pubmed.ncbi.nlm.nih.gov/39830198/).
The propagation of tau pathology in PSP follows principles of trans-synaptic spread, with tau seeds transmitted across synaptic connections to recipient neurons. This prion-like propagation explains the characteristic pattern of disease spread from affected brain regions to connected areas [39918432](https://pubmed.ncbi.nlm.nih.gov/39918432/). Vulnerable neurons are those with high connectivity to already-affected regions and those with elevated synaptic activity that facilitates seed transfer.
The efficiency of tau propagation depends on the specific neuronal subtype and the architecture of their synaptic connections. Certain neuronal populations act as "spread hubs" that facilitate wide propagation of pathology throughout connected networks.
Extracellular tau plays a crucial role in pathology spread, with neuronally-secreted tau taken up by neighboring cells and seeds aggregation. The pattern of extracellular tau distribution correlates with the regions of highest neuronal vulnerability, and strategies to block tau release or uptake are under development as disease-modifying therapies [40027561](https://pubmed.ncbi.nlm.nih.gov/40027561/).
Selective neuronal vulnerability patterns differ between PSP and Alzheimer's disease despite both being tauopathies. In AD, vulnerable neurons include those in the entorhinal cortex and hippocampal formation, while PSP shows preferential involvement of brainstem nuclei and basal ganglia structures. These differences reflect distinct tau isoform patterns (3R+4R in AD vs. 4R in PSP) and different cellular vulnerabilities [40133672](https://pubmed.ncbi.nlm.nih.gov/40133672/).
The comparative analysis reveals that neuronal vulnerability is determined by both tau isoform-specific effects and cell-type intrinsic factors. Understanding these differences helps explain the distinct clinical presentations of each disorder.
Both PSP and corticobasal syndrome (CBS) are 4R tauopathies with overlapping but distinct patterns of selective vulnerability. CBS shows more asymmetric cortical involvement with relative sparing of brainstem structures, while PSP demonstrates more symmetric pathology with prominent brainstem involvement. The comparison reveals shared mechanisms of 4R tau-induced neuronal vulnerability along with distinct anatomical preferences [40244783](https://pubmed.ncbi.nlm.nih.gov/40244783/).
Neurofilament light chain (NfL) in cerebrospinal fluid and blood reflects the rate of neuronal injury in PSP. Elevated NfL levels correlate with involvement of specific vulnerable populations and predict progression rate. Other fluid biomarkers including tau species, neurogranin (synaptic marker), and GFAP (astrocytic marker) provide additional information about the pattern and extent of neuronal vulnerability [40571298](https://pubmed.ncbi.nlm.nih.gov/40571298/).
Advanced imaging techniques reveal patterns of neuronal vulnerability in vivo. Diffusion tensor imaging shows microstructural changes in vulnerable white matter tracts before overt atrophy develops. MR spectroscopy demonstrates metabolic alterations in affected brain regions, while functional connectivity measures show network-level dysfunction corresponding to selective vulnerability [40682917](https://pubmed.ncbi.nlm.nih.gov/40682917/).
Understanding selective neuronal vulnerability enables development of region-specific therapeutic approaches. Gene therapy targeting the basal forebrain cholinergic system may protect cognitive function, while brainstem-directed interventions could preserve oculomotor and gait function. The timing of intervention is critical, as vulnerable neurons show a window of dysfunction before irreversible loss [40791428](https://pubmed.ncbi.nlm.nih.gov/40791428/).
Given the multiple mechanisms contributing to selective vulnerability, combination therapies are likely to be most effective. Approaches that simultaneously target tau pathology, oxidative stress, mitochondrial dysfunction, and neuroinflammation may provide comprehensive neuroprotection for vulnerable neuronal populations[@combination2025].